Difference between revisions of "Team:XMU-China/Public Engagement"

Line 247: Line 247:
 
                     Consulting the Chief Physician Weiwei Tang in Medical Oncology
 
                     Consulting the Chief Physician Weiwei Tang in Medical Oncology
 
                 </div>
 
                 </div>
                 <p>This year, team XMU-China developed new methods named ABCD System and OMVs Treatment for detecting and treating diseases. In order to prove the feasibility of our project, we consulted the Chief Physician Weiwei Tang in Medical Oncology, The First Affiliated Hospital of Xiamen University, on August 23th. We introduced briefly the structure and function of our self-designed hardware Eye of Agamotto(EA) to Dr.Tang. During the talk, Dr.Tang appreciated it that our ideas are innovative and helpful. What’s more, Dr.Tang also told us those frequently-used and classical clinical detection methods, like ELISA, CLIA and so on. Most of which are time-consuming, expensive and complex, compared with EA. As for EA, Dr.Tang agreed with our  proposals that we are going to make EA widely used among basic medical institutions, especially in remote, and poverty-stricken areas because of its convenient and practicability. But it’s worth noting that today there is an authoritative method for disease-diagnose, i.e., pathological diagnosis. So our detection method would just serves as a kind of screening tool rather than diagnosis method, according to Tang’s suggestion. </p>
+
                 <p>This year, team XMU-China developed new methods named ABCD System and OMVs Treatment for detecting and treating diseases. In order to prove the feasibility of our project, we consulted the Chief Physician Weiwei Tang in Medical Oncology, The First Affiliated Hospital of Xiamen University, on August 23th. We introduced briefly the structure and function of our self-designed hardware Eye of <i>Fang</i> to Dr.Tang. During the talk, Dr.Tang appreciated it that our ideas are innovative and helpful. What’s more, Dr.Tang also told us those frequently-used and classical clinical detection methods, like ELISA, CLIA and so on. Most of which are time-consuming, expensive and complex, compared with EA. As for EA, Dr.Tang agreed with our  proposals that we are going to make EA widely used among basic medical institutions, especially in remote, and poverty-stricken areas because of its convenient and practicability. But it’s worth noting that today there is an authoritative method for disease-diagnose, i.e., pathological diagnosis. So our detection method would just serves as a kind of screening tool rather than diagnosis method, according to Tang’s suggestion. </p>
 
                 <p class="F3"><img src="https://static.igem.org/mediawiki/2018/9/9f/T--XMU-China--Entrepreneurship-6.png"><img src="https://static.igem.org/mediawiki/2018/6/64/T--XMU-China--hp-%3Di.png"></p>
 
                 <p class="F3"><img src="https://static.igem.org/mediawiki/2018/9/9f/T--XMU-China--Entrepreneurship-6.png"><img src="https://static.igem.org/mediawiki/2018/6/64/T--XMU-China--hp-%3Di.png"></p>
 
             </section>
 
             </section>

Revision as of 16:25, 17 October 2018

Team:XMU-China/Engagement - 2018.igem.org

Engagement